Related Experiment Video
Updated: Jul 19, 2026

Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae
Published on: March 25, 2015
CircZNF609 sponges miR-135b to up-regulate SEMA3A expression to alleviate ox-LDL-induced atherosclerosis
Jian Hou1, Lingling Zheng2, Xiangyun Li3
1Department of Cardiology, The Second Affiliated Hospital of Shandong First Medical University, No. 366, Taishan Street, Tai'an, 271021, Shandong, People's Republic of China.
Abstract:
The initiation and progression of atherosclerotic plaque caused by abnormal lipid metabolism is one of the main causes of atherosclerosis (AS). Lipid droplet accumulation has become a novel research pointcut for AS treatment in recent years. In AS patients, miR-135b level was up-regulated relative to the normal cases, which showed negative correlations with the levels of Semaphorin 3A (SEMA3A) and circZNF609, separately. The U937-derived macrophages were cultured with ox-LDL to establish AS models in vitro. After that, the lipid accumulation, inflammation, mitochondrial dysfunction and cell death were evaluated by ORO, ELISA, RT-qPCR, western blot, JC-1 and FCM assays respectively. Transfection of the circZNF609 expression vector notably declined lipid accumulation, attenuated inflammation, reduced mitochondrial dysfunction and inhibited cell death in ox-LDL-stimulated cells. The direct binding of miR-135b to circZNF609 in vitro was confirmed using RIP assay, and SEMA3A expression was up-regulated by circZNF609 overexpression. After manipulating the endogenous expressions of circZNF609, miR-135b and SEMA3A, the above damages in ox-LDL-stimulated cells were rescued by inhibition of miR-135b expression and overexpression of circZNF609 or SEMA3A. Besides, the AS mice model was built to demonstrate the excessive lipid accumulation, increasing inflammation and cell death in AS pathogenesis according to the results of HE staining, ELISA and IHC assays, while these damages were reversed after overexpression of circZNF609 or SEMA3A. In AS models, overexpressed circZNF609 prevents the AS progression through depleting miR-135b expression and subsequent up-regulation of SEMA3A expression to overwhelm lipid accumulation, mitochondrial dysfunction and cell death.
Insights
Circular RNA ZNF609 (circZNF609) overexpression mitigates atherosclerosis by downregulating miR-135b and upregulating Semaphorin 3A (SEMA3A), reducing lipid accumulation and inflammation.
Area of Science:
- Cardiovascular Biology
- Molecular Biology
- Biochemistry
Background:
- Atherosclerosis (AS) pathogenesis involves abnormal lipid metabolism and lipid droplet accumulation.
- MicroRNA-135b (miR-135b) is upregulated in AS patients, inversely correlating with Semaphorin 3A (SEMA3A) and circZNF609 levels.
Purpose of the Study:
- To investigate the role of circZNF609 in mitigating AS progression.
- To elucidate the molecular mechanism involving miR-135b and SEMA3A in AS.
Main Methods:
- In vitro AS models using ox-LDL-stimulated U937 macrophages.
- In vivo AS mouse models.
- Assays included ORO, ELISA, RT-qPCR, western blot, JC-1, FCM, RIP, HE staining, and IHC.
Main Results:
- Overexpression of circZNF609 reduced lipid accumulation, inflammation, mitochondrial dysfunction, and cell death in vitro.
- circZNF609 directly binds to miR-135b, and circZNF609 overexpression upregulates SEMA3A.
- Inhibition of miR-135b or overexpression of circZNF609/SEMA3A rescued AS-related damages.
- In vivo, circZNF609/SEMA3A overexpression reversed AS progression.
Conclusions:
- Overexpressed circZNF609 inhibits AS progression by depleting miR-135b and upregulating SEMA3A.
- This mechanism alleviates lipid accumulation, mitochondrial dysfunction, and cell death in AS models.
More Related Videos
10:57Using In Vivo and Tissue and Cell Explant Approaches to Study the Morphogenesis and Pathogenesis of the Embryonic and Perinatal Aorta
Published on: September 12, 2017
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019